BACKGROUND: Activation of both type 1 and type 2 tumor necrosis factor (TNF) receptors (TNFR1 and TNFR2) confers cytoprotection in cardiac myocytes. Noting that the scaffolding protein TNF receptor-associated factor 2 (TRAF2) is common to both TNF receptors, we hypothesized that the cytoprotective responses of TNF were mediated through TRAF2. METHODS AND RESULTS: Mice with cardiac-restricted overexpression of low levels of TNF (MHCsTNF(3)) and TRAF2 (MHC-TRAF2(LC)) and mice lacking TNFR1, TNFR2, and TNFR1/TNFR2 were subjected to ischemia (30 minutes) reperfusion (30 minutes) injury ex vivo using a Langendorff apparatus. MHCsTNF(3) mice were protected against ischemia-reperfusion injury as shown by a significant approximately 30% greater left ventricular developed pressure, approximately 80% lower creatine kinase release, and Evans blue dye uptake compared with littermates. The extent of ischemia-reperfusion induced injury was similar in wild-type, TNFR1, and TNFR2 deficient mice; however, mice lacking TNFR1/TNFR2 had a significant approximately 40% lower left ventricular developed pressure, a approximately 65% greater creatine kinase release, and approximately 40% greater Evans blue dye uptake compared with littermates. Interestingly, MHC-TRAF2(LC) mice had a significant approximately 50% lower left ventricular developed pressure, a approximately 70% lower creatine kinase release, and approximately 80% lower Evans blue dye uptake compared with littermate controls after ischemia-reperfusion injury. Biochemical analysis of the MHC-TRAF2(LC) hearts showed that there was activation of nuclear factor-kappaB but not c-Jun N-terminal kinase activation. CONCLUSIONS: Taken together, these results suggest that TNF confers cytoprotection in the heart through TRAF2-mediated activation of nuclear factor-kappaB.
BACKGROUND: Activation of both type 1 and type 2 tumor necrosis factor (TNF) receptors (TNFR1 and TNFR2) confers cytoprotection in cardiac myocytes. Noting that the scaffolding protein TNF receptor-associated factor 2 (TRAF2) is common to both TNF receptors, we hypothesized that the cytoprotective responses of TNF were mediated through TRAF2. METHODS AND RESULTS:Mice with cardiac-restricted overexpression of low levels of TNF (MHCsTNF(3)) and TRAF2 (MHC-TRAF2(LC)) and mice lacking TNFR1, TNFR2, and TNFR1/TNFR2 were subjected to ischemia (30 minutes) reperfusion (30 minutes) injury ex vivo using a Langendorff apparatus. MHCsTNF(3) mice were protected against ischemia-reperfusion injury as shown by a significant approximately 30% greater left ventricular developed pressure, approximately 80% lower creatine kinase release, and Evans blue dye uptake compared with littermates. The extent of ischemia-reperfusion induced injury was similar in wild-type, TNFR1, and TNFR2 deficient mice; however, mice lacking TNFR1/TNFR2 had a significant approximately 40% lower left ventricular developed pressure, a approximately 65% greater creatine kinase release, and approximately 40% greater Evans blue dye uptake compared with littermates. Interestingly, MHC-TRAF2(LC) mice had a significant approximately 50% lower left ventricular developed pressure, a approximately 70% lower creatine kinase release, and approximately 80% lower Evans blue dye uptake compared with littermate controls after ischemia-reperfusion injury. Biochemical analysis of the MHC-TRAF2(LC) hearts showed that there was activation of nuclear factor-kappaB but not c-Jun N-terminal kinase activation. CONCLUSIONS: Taken together, these results suggest that TNF confers cytoprotection in the heart through TRAF2-mediated activation of nuclear factor-kappaB.
Authors: W C Yeh; A Shahinian; D Speiser; J Kraunus; F Billia; A Wakeham; J L de la Pompa; D Ferrick; B Hum; N Iscove; P Ohashi; M Rothe; D V Goeddel; T W Mak Journal: Immunity Date: 1997-11 Impact factor: 31.745
Authors: Maria Brown; Michael McGuinness; Terry Wright; Xiaoping Ren; Yang Wang; Gregory P Boivin; Harvey Hahn; Arthur M Feldman; W Keith Jones Journal: Am J Physiol Heart Circ Physiol Date: 2005-02-04 Impact factor: 4.733
Authors: Stamatis Papathanasiou; Steffen Rickelt; Maria Eugenia Soriano; Tobias G Schips; Harald J Maier; Constantinos H Davos; Aimilia Varela; Loukas Kaklamanis; Douglas L Mann; Yassemi Capetanaki Journal: Nat Med Date: 2015-08-17 Impact factor: 53.440
Authors: Babak Razani; Haixia Zhang; P Christian Schulze; Joel D Schilling; John Verbsky; Irfan J Lodhi; Veli K Topkara; Chu Feng; Trey Coleman; Attila Kovacs; Daniel P Kelly; Jeffrey E Saffitz; Gerald W Dorn; Colin G Nichols; Clay F Semenkovich Journal: J Biol Chem Date: 2011-07-08 Impact factor: 5.157
Authors: Dominic P Del Re; Dulguun Amgalan; Andreas Linkermann; Qinghang Liu; Richard N Kitsis Journal: Physiol Rev Date: 2019-10-01 Impact factor: 37.312
Authors: Luigi Adamo; Lora J Staloch; Cibele Rocha-Resende; Scot J Matkovich; Wenlong Jiang; Geetika Bajpai; Carla J Weinheimer; Attila Kovacs; Joel D Schilling; Philip M Barger; Deepta Bhattacharya; Douglas L Mann Journal: JCI Insight Date: 2018-06-07
Authors: Vijay G Divakaran; Sarah Evans; Veli K Topkara; Abhinav Diwan; Jana Burchfield; Feng Gao; Jianwen Dong; Huei-Ping Tzeng; Natarajan Sivasubramanian; Philip M Barger; Douglas L Mann Journal: Circ Heart Fail Date: 2013-03-14 Impact factor: 8.790